Investor Presentaiton

Investor presentation First three months of 2017 Slide 24 Novo Nordisk has leading positions in diabetes, haemophilia and growth disorders Diabetes Haemophilia Growth disorders DKK billion Market value DKK Market value DKK Market value Novo Nordisk value market share billion Global market position Novo Nordisk value market share Global market position billion Novo Nordisk value market share Global market position 500 50% 70 50% 25 50% #1 #2 #1 60 400 300 40% 40% 20 40% 50 30% 30% 15 30% 40 30 200 20% 20% 10 20% CAGR¹ value: 17.7% 20 CAGR¹ value: 2.7% CAGR¹ value: 1.7% 100 10% 10% 5- - 10% 10 0 Feb 2012 0% 0 Feb 2017 FY 2012 1 CAGR for 5-year period Source: IMS MAT February, 2017 value figures Note: Annual sales figures for Haemophilia A, B and inhibitor segment 1 CAGR for 5-year period 0% 0 FY 2016 Feb 2012 1 CAGR for 5-year period 0% Feb 2017 Source: IMS MAT February, 2017 value figures changing diabetes® Source: Company reports novo nordisk

View entire presentation